

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 December 2002 (27.12.2002)

PCT

(10) International Publication Number
WO 02/102800 A1

(51) International Patent Classification⁷: C07D 413/04,
401/14, 409/14, A61K 31/505, A61P 3/10, 25/28, 37/00

Mark [US/US]; 86 Faulkner Hill Road, Acton, MA 01720
(US).

(21) International Application Number: PCT/US02/19186

(74) Agents: HALEY, James, F.; c/o Fish & Neave, 1251 Avenue of the Americas, New York, NY 10020 et al. (US).

(22) International Filing Date: 14 June 2002 (14.06.2002)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(26) Publication Language: English

Published:

— with international search report

(30) Priority Data:
60/298,646 15 June 2001 (15.06.2001) US

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(71) Applicant (for all designated States except US): VERTEX
PHARMACEUTICALS INCORPORATED [US/US];
130 Waverly Street, Cambridge, MA 02139-4242 (US).


(72) Inventors; and

(75) Inventors/Applicants (for US only): MOON, Young,
Choon [KR/US]; 1 Great Rock Road, Lexington, MA
02173 (US). GREEN, Jeremy [US/US]; 21 Greystone
Court, Burlington, MA 01803 (US). DAVIES, Robert
[US/US]; 65 Orient Avenue, Arlington, MA 02474 (US).
CHOQUETTE, Deb [US/US]; 17 Blakely Road, Med-
ford, MA 02155 (US). PIERCE, Albert [US/US]; 24
Bates Street, Cambridge, MA 02140 (US). LEDEBOER,

A1

(54) Title: 5-(2-AMINOPYRIMIDIN-4-YL) BENZISOXAZOLES AS PROTEIN KINASE INHIBITORS

WO 02/102800



(I)

(57) Abstract: Described herein are benzisoxazole compounds of formula I or a pharmaceutically acceptable derivative or prodrug thereof, wherein A-B is N-O or O-N; Ar is an optionally substituted C₅-10 aryl group; R¹ is hydrogen or an optionally substituted group selected from C₁-10 aliphatic, C₅-10 aryl, C₆-12 aralkyl, C₃-10 heterocyclyl, or C₄-12 heterocyclylalkyl; and T, n, R² and R³ are as described in the specification. These compounds are inhibitors of protein kinases, particularly inhibitors of GSK-3 and JAK mammalian protein kinases. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of utilizing those compounds and compositions in the treatment of various - protein kinase mediated disorders.

B1

5-(2-AMINOPYRIMIDIN-4-YL) BENZISOXAZOLES AS PROTEIN KINASE INHIBITORS

Field of the Invention

[0001] The present invention is in the field of medicinal chemistry and relates to compounds that are 5 protein kinase inhibitors, compositions comprising such compounds and methods of use. More particularly, the compounds are inhibitors of GSK-3 and JAK and are useful for treating disease states, such as diabetes and Alzheimer's disease, that are alleviated by GSK-3 10 inhibitors, and allergic disorders, autoimmune diseases, and conditions associated with organ transplantation that are alleviated by JAK inhibitors.

Background of the Invention

15 [0002] The search for new therapeutic agents has been greatly aided in recent years by a better understanding of the structure of enzymes and other biomolecules associated with target diseases. One important class of enzymes that has been the subject of extensive study is 20 the protein kinases.

[0003] Protein kinases mediate intracellular signal transduction. They do this by effecting a phosphoryl

transfer from a nucleoside triphosphate to a protein acceptor that is involved in a signaling pathway. There are a number of kinases and pathways through which extracellular and other stimuli cause a variety of 5 cellular responses to occur inside the cell. Examples of such stimuli include environmental and chemical stress signals (e.g. osmotic shock, heat shock, ultraviolet radiation, bacterial endotoxin, H₂O₂), cytokines (e.g. interleukin-1 (IL-1) and tumor necrosis factor α (TNF- α)), and growth factors (e.g. granulocyte macrophage-colony-stimulating factor (GM-CSF), and fibroblast growth factor (FGF)). An extracellular stimulus may effect one 10 or more cellular responses related to cell growth, migration, differentiation, secretion of hormones, 15 activation of transcription factors, muscle contraction, glucose metabolism, control of protein synthesis and regulation of cell cycle.

[0004] Many disease states are associated with abnormal cellular responses triggered by protein kinase-mediated events. These diseases include autoimmune 20 diseases, inflammatory diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies and asthma, Alzheimer's disease or hormone-related diseases.

Accordingly, there has been a substantial effort in medicinal chemistry to find protein kinase inhibitors 25 that are effective as therapeutic agents. A challenge has been to find protein kinase inhibitors that act in a selective manner. Since there are numerous protein 30 kinases that are involved in a variety of cellular responses, non-selective inhibitors may lead to unwanted side effects.

- 3 -

[0005] Glycogen synthase kinase-3 (GSK-3) is a serine/threonine protein kinase comprised of α and β isoforms that are each encoded by distinct genes [Coghlan et al., *Chemistry & Biology*, 7, 793-803 (2000); Kim and Kimmel, *Curr. Opinion Genetics Dev.*, 10, 508-514 (2000)]. GSK-3 has been implicated in various diseases including diabetes, Alzheimer's disease, CNS disorders such as manic depressive disorder and neurodegenerative diseases, and cardiomyocyte hypertrophy [WO 99/65897; WO 00/38675; and Haq et al., *J. Cell Biol.* (2000) 151, 1117]. These diseases may be caused by, or result in, the abnormal operation of certain cell signaling pathways in which GSK-3 plays a role. GSK-3 has been found to phosphorylate and modulate the activity of a number of regulatory proteins. These include glycogen synthase which is the rate limiting enzyme necessary for glycogen synthesis, the microtubule associated protein Tau, the gene transcription factor β -catenin, the translation initiation factor eIF2B, as well as ATP citrate lyase, axin, heat shock factor-1, c-Jun, c-Myc, c-Myb, CREB, and CEPB α . These diverse targets implicate GSK-3 in many aspects of cellular metabolism, proliferation, differentiation and development.

[0006] In a GSK-3 mediated pathway that is relevant for the treatment of type II diabetes, insulin-induced signaling leads to cellular glucose uptake and glycogen synthesis. Along this pathway, GSK-3 is a negative regulator of the insulin-induced signal. Normally, the presence of insulin causes inhibition of GSK-3 mediated phosphorylation and deactivation of glycogen synthase. The inhibition of GSK-3 leads to increased glycogen synthesis and glucose uptake [Klein et al., *PNAS*, 93,

- 4 -

8455-9 (1996); Cross et al., *Biochem. J.*, **303**, 21-26 (1994); Cohen, *Biochem. Soc. Trans.*, **21**, 555-567 (1993); Massillon et al., *Biochem J.* **299**, 123-128 (1994)].

However, in a diabetic patient where the insulin response
5 is impaired, glycogen synthesis and glucose uptake fail
to increase despite the presence of relatively high blood
levels of insulin. This leads to abnormally high blood
levels of glucose with acute and chronic effects that may
ultimately result in cardiovascular disease, renal
10 failure and blindness. In such patients, the normal
insulin-induced inhibition of GSK-3 fails to occur. It
has also been reported that in patients with type II
diabetes, GSK-3 is overexpressed [WO 00/38675].

Therapeutic inhibitors of GSK-3 are therefore potentially
15 useful for treating diabetic patients suffering from an
impaired response to insulin.

[0007] GSK-3 activity has also been associated with
Alzheimer's disease. This disease is characterized by
the well-known β -amyloid peptide and the formation of
20 intracellular neurofibrillary tangles. The
neurofibrillary tangles contain hyperphosphorylated Tau
protein where Tau is phosphorylated on abnormal sites.
GSK-3 has been shown to phosphorylate these abnormal
sites in cell and animal models. Furthermore, inhibition
25 of GSK-3 has been shown to prevent hyperphosphorylation
of Tau in cells [Lovestone et al., *Current Biology* **4**,
1077-86 (1994); Brownlees et al., *Neuroreport* **8**, 3251-55
(1997)]. Therefore, it is believed that GSK-3 activity
may promote generation of the neurofibrillary tangles and
30 the progression of Alzheimer's disease.

[0008] Another substrate of GSK-3 is β -catenin which
is degraded after phosphorylation by GSK-3. Reduced
levels of β -catenin have been reported in schizophrenic

- patients and have also been associated with other diseases related to increase in neuronal cell death [Zhong et al., *Nature*, 395, 698-702 (1998); Takashima et al., *PNAS*, 90, 7789-93 (1993); Pei et al., *J. Neuropathol. Exp.*, 56, 70-78 (1997); Smith et al., *Bio-org. Med. Chem.* 11, 635-639 (2001)].
- [0009] Small molecule inhibitors of GSK-3 have recently been reported [WO 99/65897 (Chiron) and WO 00/38675 (SmithKline Beecham)].
- [0010] The Janus kinases (JAK) are a family of tyrosine kinases consisting of JAK1, JAK2, JAK3 and TYK2. The JAKs play a critical role in cytokine signaling. The down-stream substrates of the JAK family of kinases include the signal transducer and activator of transcription (STAT) proteins. JAK/STAT signaling has been implicated in the mediation of many abnormal immune responses such as allergies, asthma, autoimmune diseases such as transplant rejection, rheumatoid arthritis, amyotrophic lateral sclerosis and multiple sclerosis as well as in solid and hematologic malignancies such as leukemias and lymphomas. The pharmaceutical intervention in the JAK/STAT pathway has been reviewed [Frank Mol. Med. 5: 432-456 (1999) & Seidel, et al, *Oncogene* 19: 2645-2656 (2000)].
- [0011] JAK1, JAK2, and TYK2 are ubiquitously expressed, while JAK3 is predominantly expressed in hematopoietic cells. JAK3 binds exclusively to the common cytokine receptor gamma chain (γ_c) and is activated by IL-2, IL-4, IL-7, IL-9, and IL-15. The proliferation and survival of murine mast cells induced by IL-4 and IL-9 have, in fact, been shown to be dependent on JAK3- and γ_c -signaling [Suzuki et al, *Blood* 96: 2172-2180 (2000)].

[0012] Cross-linking of the high-affinity immunoglobulin (Ig) E receptors of sensitized mast cells leads to a release of proinflammatory mediators, including a number of vasoactive cytokines resulting in acute allergic, or immediate (type I) hypersensitivity reactions [Gordon et al, Nature 346: 274-276 (1990) & Galli, N. Engl. J. Med., 328: 257-265 (1993)]. A crucial role for JAK3 in IgE receptor-mediated mast cell responses *in vitro* and *in vivo* has been established [Malaviya, et al, Biochem. Biophys. Res. Commun. 257: 807-813 (1999)]. In addition, the prevention of type I hypersensitivity reactions, including anaphylaxis, mediated by mast cell-activation through inhibition of JAK3 has also been reported [Malaviya et al, J. Biol. Chem. 274:27028-27038 (1999)]. Targeting mast cells with JAK3 inhibitors modulated mast cell degranulation *in vitro* and prevented IgE receptor/antigen-mediated anaphylactic reactions *in vivo*.

[0013] A recent study described the successful targeting of JAK3 for immunosuppression and allograft acceptance. The study demonstrated a dose-dependent survival of Buffalo heart allograft in Wistar Furth recipients upon administration of inhibitors of JAK3 indicating the possibility of regulating unwanted immune responses in graft versus host disease [Kirken, transpl. proc. 33: 3268-3270 (2001)].

[0014] IL-4-mediated STAT-phosphorylation has been implicated as the mechanism involved in early and late stages of rheumatoid arthritis (RA). Up-regulation of proinflammatory cytokines in RA synovium and synovial fluid is a characteristic of the disease. It has been demonstrated that IL-4-mediated activation of IL-4/STAT pathway is mediated through the Janus Kinases (JAK 1 & 3)

- 7 -

and that IL-4-associated JAK kinases are expressed in the RA synovium [Muller-Ladner, et al, J. Immunol. 164: 3894-3901 (2000)].

5 [0015] Familial amyotrophic lateral sclerosis (FALS) is a fatal neurodegenerative disorder affecting about 10% of ALS patients. The survival rates of FALS mice were increased upon treatment with a JAK3 specific inhibitor.

This suggested that JAK3 plays a role in FALS [Trieu, et al, Biochem. Biophys. Res. Commun. 267: 22-25 (2000)].

10 [0016] Signal transducer and activator of transcription (STAT) proteins are activated by, among others, the JAK family kinases. Results from a recent study suggested the possibility of intervention in the JAK/STAT signaling pathway by targeting JAK family

15 kinases with specific inhibitors for the treatment of leukemia [Sudbeck, et al, Clin. Cancer Res. 5: 1569-1582 (1999)]. JAK3 specific compounds were shown to inhibit the clonogenic growth of JAK3-expressing cell lines DAUDI, RAMOS, LC1; 19, NALM-6, MOLT-3 and HL-60.

20 [0017] In animal models, TEL/JAK2 fusion proteins have induced myeloproliferative disorders and in hematopoietic cell lines, introduction of TEL/JAK2 resulted in activation of STAT1, STAT3, STAT5, and cytokine-independent growth [Schwaller, et al, EMBO J. 17: 5321-5333 (1998)].

25 [0018] Inhibition of JAK3 and TYK2 abrogated tyrosine phosphorylation of STAT3, and inhibited cell growth of mycosis fungoides, a form of cutaneous T cell lymphoma. These results implicated JAK family kinases in the 30 constitutively activated JAK/STAT pathway that is present in mycosis fungoides [Nielsen, et al, Proc. Nat. Acad. Sci. U.S.A. 94: 6764-6769 (1997)]. Similarly, STAT3, STAT5, JAK1 and JAK2 were demonstrated to be

- 8 -


constitutively activated in mouse T cell lymphoma characterized initially by LCK over-expression, thus further implicating the JAK/STAT pathway in abnormal cell growth [Yu, et al, J. Immunol. 159: 5206-5210 (1997)].

5 In addition, IL-6-mediated STAT3 activation was blocked by an inhibitor of JAK, leading to sensitization of myeloma cells to apoptosis [Catlett-Falcone, et al, Immunity 10:105-115 (1999)].

[0019] There is a continued need to find new
10 therapeutic agents to treat human diseases. Accordingly, there is a great need to develop inhibitors of GSK-3 and JAK protein kinases that are useful in treating various diseases or conditions associated with GSK-3 and JAK activation, particularly given the inadequate treatments
15 currently available for the majority of these disorders.

Description of the Invention

[0020] It has now been found that compounds of this invention and pharmaceutical compositions thereof are effective as protein kinase inhibitors, particularly as inhibitors of GSK-3 and JAK. These compounds have the general formula I:



25

or a pharmaceutically acceptable derivative or prodrug thereof, wherein:

A-B is N-O or O-N;

- Ar is an optionally substituted C₅₋₁₀ aryl group;
T is a C₁₋₄ alkylidene chain wherein one or two methylene units of T are optionally and independently replaced by O, NR, S, C(O), C(O)NR, NRC(O)NR, SO₂, SO₂NR, NRSO₂, NRSO₂NR, CO₂, OC(O), NRCO₂, or OC(O)NR;
- 5 n is zero or one;
- R¹ is hydrogen or an optionally substituted group selected from C₁₋₁₀ aliphatic, C₅₋₁₀ aryl, C₆₋₁₂ aralkyl, C₃₋₁₀ heterocyclyl, or C₄₋₁₂ heterocyclylalkyl;
- 10 each R² is independently selected from R, halo, CN, OR, N(R)₂, SR, C(=O)R, CO₂R, CONR₂, NRC(=O)R, NRCO₂(C₁₋₆ aliphatic), OC(=O)R, SO₂R, S(=O)R, SO₂NR₂, or NRSO₂(C₁₋₆ aliphatic);
- each R³ is independently selected from R, halo, CN, OR,
- 15 N(R)₂, SR, C(=O)R, CO₂R, CONR₂, NRC(=O)R, NRCO₂(C₁₋₆ aliphatic), OC(=O)R, SO₂R, S(=O)R, SO₂NR₂, or NRSO₂(C₁₋₆ aliphatic); and
- each R is independently selected from hydrogen, a C₁₋₈ aliphatic group, or two R on the same nitrogen are taken together with the nitrogen to form a 4-8 membered heterocyclic ring having 1-3 heteroatoms selected from nitrogen, oxygen or sulfur.
- 20 [0021] As used herein, the following definitions shall apply unless otherwise indicated.
- 25 [0022] The phrase "optionally substituted" is used interchangeably with the phrase "substituted or unsubstituted." Unless otherwise indicated, an optionally substituted group may have a substituent at each substitutable position of the group, and each substitution is independent of the other.
- 30 [0023] The term "aliphatic" or "aliphatic group" as used herein means a straight-chain or branched C_{1-C₁₀} hydrocarbon chain that is completely saturated or that

- 10 -

contains one or more units of unsaturation, or a monocyclic C₃-C₈ hydrocarbon or bicyclic C₈-C₁₂ hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic (also referred to herein as "carbocycle" or "cycloalkyl"), that has a single point of attachment to the rest of the molecule wherein any individual ring in said bicyclic ring system has 3-7 members. For example, suitable aliphatic groups include substituted or unsubstituted linear or branched alkyl, alkenyl, or alkynyl groups and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.

[0024] The terms "alkyl", "alkoxy", "hydroxyalkyl", "alkoxyalkyl", and "alkoxycarbonyl", used alone or as part of a larger moiety include both straight and branched chains containing one to twelve carbon atoms. The terms "alkenyl" and "alkynyl" used alone or as part of a larger moiety shall include both straight and branched chains containing two to twelve carbon atoms.

[0025] The terms "haloalkyl", "haloalkenyl" and "haloalkoxy" means alkyl, alkenyl or alkoxy, as the case may be, substituted with one or more halogen atoms. The term "halogen" means F, Cl, Br, or I.

[0026] The term "heteroatom" means nitrogen, oxygen or sulfur and includes any oxidized form of nitrogen and sulfur, and the quaternized form of any basic nitrogen. Also, the term "nitrogen" includes a substitutable nitrogen of a heterocyclic ring. As an example, in a saturated or partially unsaturated ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, the nitrogen may be N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or NR⁺ (as in N-substituted pyrrolidinyl). It is understood that the compounds of

this invention are limited to those that can exist in nature as stable chemical compounds.

5 [0027] The term "unsaturated", as used herein, means that a moiety has one or more units of unsaturation, and includes aryl rings.

10 [0028] The term "aryl", used alone or as part of a larger moiety as in "aralkyl", "aralkoxy", or "aryloxyalkyl", refers to monocyclic, bicyclic and tricyclic ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring members. The term "aryl" may be used interchangeably with the term "aryl ring". The term "aryl" also refers to heteroaryl ring systems as defined 15 hereinbelow.

20 [0029] The term "heterocycle", "heterocyclyl", or "heterocyclic", as used herein means non-aromatic, monocyclic, bicyclic, or tricyclic ring systems having five to fourteen ring members in which one or more ring members is a heteroatom, wherein each ring in the system contains 3 to 7 ring members.

25 [0030] The term "heteroaryl", used alone or as part of a larger moiety as in "heteroaryalkyl" or "heteroarylalkoxy", refers to monocyclic, bicyclic and tricyclic ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic, at least one ring in the system contains one or more heteroatoms, and wherein each ring in the system contains 3 to 7 ring members. The term "heteroaryl" may 30 be used interchangeably with the term "heteroaryl ring" or the term "heteroaromatic".

[0031] An aryl (including aralkyl, aralkoxy, aryloxyalkyl and the like) or heteroaryl (including

- 12 -

heteroaralkyl and heteroarylalkoxy and the like) group may contain one or more substituents. Suitable substituents on the unsaturated carbon atom of an aryl, heteroaryl, aralkyl, or heteroaralkyl group are

5 independently selected from halogen, -R°, -OR°, -O(CH₂)_yR°, -SR°, 1,2-methylene-dioxy, 1,2-ethylenedioxy, phenyl (Ph) optionally substituted with R°, -O(Ph) optionally substituted with R°, -CH₂(Ph) optionally substituted with R°, 5-8

10 membered heteroaryl optionally substituted with R°, 5-8 membered heterocycle optionally substituted with R°, -NO₂, -CN, -N(R°)₂, -N(R°)(CH₂)_yR°, -NR°C(O)R°, -NR°C(O)N(R°)₂, -NR°CO₂R°, -NR°NR°C(O)R°, -NR°NR°C(O)N(R°)₂, -NR°NR°CO₂R°, -C(O)C(O)R°, -C(O)CH₂C(O)R°, -CO₂R°, -C(O)R°, -C(O)N(R°)₂,

15 -OC(O)N(R°)₂, -S(O)₂R°, -SO₂N(R°)₂, -S(O)R°, -NR°SO₂N(R°)₂, -NR°SO₂R°, -C(=S)N(R°)₂, -C(=NH)-N(R°)₂, or -(CH₂)_yNHC(O)R°, wherein each R° is independently selected from hydrogen, optionally substituted C₁₋₆ aliphatic, phenyl, -O(Ph), or -CH₂(Ph), wherein y is 0-6. When R° is a C₁₋₆ aliphatic group or a phenyl ring, it may be substituted with one or more substituents selected from -NH₂, -NH(C₁₋₄ aliphatic), -N(C₁₋₄ aliphatic)₂, -S(O)(C₁₋₄ aliphatic), -SO₂(C₁₋₄ aliphatic), halogen, -(C₁₋₄ aliphatic), OH, -O(C₁₋₄ aliphatic), NO₂, CN, CO₂H, -CO₂(C₁₋₄ aliphatic), -O(halo C₁₋₄ aliphatic), or -halo(C₁₋₄ aliphatic); wherein each C₁₋₄ aliphatic is unsubstituted.

20

25

[0032] An aliphatic group or a non-aromatic heterocyclic ring may contain one or more substituents. A saturated carbon of an aliphatic group or of a non-aromatic heterocyclic ring may have one or more substituents. Suitable substituents on the saturated carbon of an aliphatic group or of a non-aromatic

- 13 -

heterocyclic ring are selected from those listed above for the unsaturated carbon of an aryl or heteroaryl group as well as the following: =O, =S, =NNHR*, =NN(R*)₂, =N-, =NNHC(O)R*, =NNHCO₂(alkyl), =NNHSO₂(alkyl), or =NR*, where 5 each R* is independently selected from hydrogen or an optionally substituted C₁₋₆ aliphatic. When R* is C₁₋₆ aliphatic, it may be substituted with one or more substituents independently selected from -NH₂, -NH(C₁₋₄ aliphatic), -N(C₁₋₄ aliphatic)₂, halogen, C₁₋₄ aliphatic, OH, O(C₁₋₄ aliphatic), NO₂, CN, CO₂H, CO₂(C₁₋₄ aliphatic), 10 O(halo C₁₋₄ aliphatic), or halo(C₁₋₄ aliphatic); wherein each C₁₋₄ aliphatic is unsubstituted.

[0033] Substituents on the nitrogen of a non-aromatic heterocyclic ring are selected from -R*, -N(R*)₂, -C(O)R*, 15 -CO₂R*, -C(O)C(O)R*, -C(O)CH₂C(O)R*, -SO₂R*, -SO₂N(R*)₂, -C(=S)N(R*)₂, -C(=NH)-N(R*)₂, or -NR*SO₂R*; wherein each R* is independently selected from hydrogen, an optionally substituted C₁₋₆ aliphatic, optionally substituted phenyl, 20 optionally substituted -O(Ph), optionally substituted -CH₂(Ph), optionally substituted -CH₂CH₂(Ph), or an unsubstituted 5-6 membered heteroaryl or heterocyclic ring. When R* is a C₁₋₆ aliphatic group or a phenyl ring, it may be substituted with one or more substituents selected from -NH₂, -NH(C₁₋₄ aliphatic), -N(C₁₋₄ aliphatic)₂, halogen, C₁₋₄ aliphatic, OH, O(C₁₋₄ aliphatic), 25 NO₂, CN, CO₂H, CO₂(C₁₋₄ aliphatic), O(halo C₁₋₄ aliphatic), or halo(C₁₋₄ aliphatic); wherein each C₁₋₄ aliphatic is unsubstituted.

[0034] The term "alkylidene chain" refers to a 30 straight or branched carbon chain that may be fully saturated or have one or more units of unsaturation and has two points of attachment to the rest of the molecule.



- 14 -

[0035] A combination of substituents or variables is permissible only if such a combination results in a stable or chemically feasible compound. A stable compound or chemically feasible compound is one that is 5 not substantially altered when kept at a temperature of 40°C or less, in the absence of moisture or other chemically reactive conditions, for at least a week.

[0036] It will be apparent to one skilled in the art 10 that certain compounds of this invention may exist in tautomeric forms, all such tautomeric forms of the compounds being within the scope of the invention.

[0037] Unless otherwise stated, structures depicted 15 herein are also meant to include all stereochemical forms of the structure; i.e., the R and S configurations for each asymmetric center. Therefore, single stereochemical isomers as well as enantiomeric and diastereomeric mixtures of the present compounds are within the scope of the invention. Unless otherwise stated, structures depicted herein are also meant to include compounds which 20 differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by a ¹³C- or ¹⁴C-enriched carbon are within the 25 scope of this invention.

[0038] One embodiment of the present invention relates 30 to compounds which are 2,1-benzisoxazoles, represented by formula I-A shown below. Another embodiment of this invention relates to compounds which are 1,2-benzisoxazoles, represented by formula I-B shown below:



wherein Ar, T, n, R¹, and R² are as described above for formula I.

- 5 [0039] Ar is preferably a substituted or unsubstituted five or six-membered aromatic ring having zero to two ring heteroatoms selected from nitrogen, sulfur or oxygen. A more preferred Ar is a substituted or unsubstituted six-membered aromatic ring having zero to
- 10 two ring nitrogens. Most preferably, Ar group is a substituted or unsubstituted phenyl ring. Preferably, Ar is substituted with one or more substituents independently selected from C₁₋₁₀ aliphatic, C₅₋₁₀ aryl, C₆₋₁₂ aralkyl, C₃₋₁₀ heterocyclyl, C₄₋₁₂ heterocyclalkyl, halo, CN, OR, N(R)₂, SR, C(=O)R, CO₂R, CONR₂, NRC(=O)R, NRCO₂(C₁₋₆ aliphatic), OC(=O)R, SO₂R, S(=O)R, SO₂NR₂, or NRSO₂(C₁₋₆ aliphatic), or two substituents on adjacent positions are optionally taken together with their intervening atoms to form a fused 5-8 membered unsaturated or partially
- 15 unsaturated ring having zero to two heteroatoms selected from nitrogen, oxygen or sulfur; wherein R is as described above for formula I.
- 20 [0040] R¹ is preferably hydrogen or an aryl ring, such as a phenyl or pyridyl ring. Optional substituents on R¹ are independently selected from halogen, -R, -OR, -OH, -SH, -SR, protected OH (such as acyloxy), -NO₂, -CN, -NH₂, -NHR, -N(R)₂, -NHCOR, -NHCONHR, -NHCON(R)₂, -NRCOR, -NHCO₂R, -CO₂R, -CO₂H, -COR, -CONHR, -CON(R)₂, -S(O)₂R, -SO₂NH₂, -S(O)R, -SO₂NHR, or -NHS(O)₂R, where R is a C₁₋₆


- 16 -

aliphatic group or a substituted C₁₋₆ aliphatic group, preferably having one to three carbons. A particularly preferred substituent on the C₁₋₆ aliphatic group is -SO₂NH₂.

5 [0041] R² is preferably hydrogen or a C₁₋₄ alkyl group, most preferably hydrogen.






[0042] R³ is preferably hydrogen, halo, O(C₁₋₄ alkyl), or a C₁₋₄ alkyl group. Most preferably R³ is hydrogen. Representative examples of compounds of formula I-A are 10 shown below in Table 1.







Table 1. Examples of Compounds of formula I-A







No.	Structure
I-A1	
I-A2	
I-A3	

No.	Structure
I-A4	
I-A5	
I-A6	
I-A7	
I-A8	
I-A9	
I-A10	

No.	Structure
I-A11	
I-A12	
I-A13	
I-A14	
I-A15	
I-A16	
I-A17	






No.	Structure
I-A18	
I-A19	
I-A20	
I-A21	
I-A22	
I-A23	
I-A24	







- 20 -

No.	Structure
I-A25	
I-A26	
I-A27	
I-A28	
I-A29	
I-A30	
I-A31	





No.	Structure
I-A32	
I-A33	
I-A34	
I-A35	
I-A36	
I-A37	
I-A38	







- 22 -

No.	Structure
I-A39	
I-A40	
I-A41	
I-A42	
I-A43	

No.	Structure
I-A44	
I-A45	
I-A46	
I-A47	
I-A48	
I-A49	







- 24 -







No.	Structure
I-A50	
I-A51	
I-A52	
I-A53	
I-A54	
I-A55	






No.	Structure
I-A56	
I-A57	
I-A58	
I-A59	
I-A60	
I-A61	

- 26 -






No.	Structure
I-A62	
I-A63	
I-A64	
I-A65	
I-A66	
I-A67	

No.	Structure
I-A68	
I-A69	
I-A70	
I-A71	
I-A72	
I-A73	

No.	Structure
I-A74	
I-A75	
I-A76	
I-A77	
I-A78	
I-A79	

No.	Structure
I-A80	
I-A81	
I-A82	
I-A83	
I-A84	

- 30 -


No.	Structure
I-A85	
I-A86	
I-A87	
I-A88	
I-A89	

[0043] The compounds of this invention may be prepared in general by methods known to those skilled in the art

- 31 -

for analogous compounds, as illustrated by the general scheme below and by the preparative examples that follow.


Scheme I



Reagents and conditions: (a) ArCH₂CN, KOH, MeOH, room temperature (rt); (b) formic acid, rt (c) N,N-dimethylformamide dimethyl acetal, CH₃CN, 80 °C; (d) N-phenylguanidine-HCl, CH₃CN, reflux.


[0044] Scheme I above shows a synthetic route for preparing compounds of the present invention. For various Ar groups, the intermediate 3 can be obtained commercially or obtained by known methods as shown in steps (a) and (b) above. See R.B. Davis and L.C. Pizzini, J. Org. Chem., 1960, 25, 1884-1888. A Mannich reaction provides intermediate 4, which can be treated with phenylguanidine to give the desired compounds 5. It will be obvious to one skilled in the art that phenylguanidine may be replaced with other arylguanidines, which are readily available, to provide other compounds of this invention.

- 32 -

Scheme II


Reagents and conditions: (a) $R^1NHC(=NH)NH_2 \cdot HCl$, CH_3CN , reflux; (b) $4\text{-Br-C}_6H_4\text{-CH}_2CN$, KOH , $MeOH$, room temperature (rt); (c) $R^4B(OH)_2$, $Pd(PPh_3)_4$, Na_2CO_3 , dioxane

[0045] Scheme II above shows an alternative synthetic route where the pyrimidine ring is constructed before the benzisoxazole ring. Steps (a) and (b) are analogous to the corresponding steps shown above in Scheme I except that they are performed in the opposite order. Step (c) illustrates one of many ways known to those skilled in the art in which certain compounds of this invention may be modified to provide further compounds of this invention. For example, the bromo substituent of compound 8 may be replaced by other groups using standard coupling methods. R^4 is preferably an aryl or heteroaryl ring. It will be obvious to one skilled in the art that this scheme may be modified to provide other compounds of this invention.

Scheme III

- 5 Reagents and conditions: (a) NaH, DMF/THF 1:1, $R^5C(O)Cl$, ambient temp; wherein R^1 is $-C(O)R^5$; (b) R^7NCO , DMSO, ambient temp/80°C; wherein R^1 is $-C(O)NHR^7$; (c) [from the p-NO₂-phenyl carbamic esters] R^7NH_2 , DMSO/THF 1:1, 80°C; wherein R^1 is $-C(O)NHR^7$.
- 10 Alternatively, reagents and conditions for carbamate formation (not shown): (a) $R^6OC(O)Cl$, DMSO, DIPEA, ambient temp; wherein R^1 is $-C(O)OR^6$.

[0046] Scheme III shows general methods for the preparation of compounds of Formula I wherein NH- R^1 taken together form an amide (shown in step (a) above), carbamate (not shown) or a urea (shown in steps (a) and (c) or step (b) above). Acylation of the aminopyrimidine with acid chlorides, chloroformates and isocyanates provides amides, carbamates and ureas respectively. Alternatively, ureas can be generated by a nucleophilic displacement reaction with a primary or secondary amine via the corresponding p-nitrophenylcarbamate.

Scheme IV

Reagents and conditions: a) NHR°_2 , $\text{Pd}(\text{OAc})_2$, P-tBu_3 ,
 KOtBu , toluene, 90°C .

5 [0047] Scheme IV shows a general method for obtaining compounds 2 (scheme I) wherein the Ar group is substituted with an amine functionality as in 2b, and wherein R° is as described above. Compounds of type 2b may then be taken forward according to Schemes I-III.

10 [0048] The activity of a compound utilized in this invention as an inhibitor of GSK-3 or JAK kinase may be assayed *in vitro*, *in vivo* or in a cell line according to methods known in the art. *In vitro* assays include assays that determine inhibition of either the phosphorylation 15 activity or ATPase activity of activated GSK-3 or JAK. Alternate *in vitro* assays quantitate the ability of the inhibitor to bind to GSK-3 or JAK. Inhibitor binding may be measured by radiolabelling the inhibitor prior to 20 binding, isolating the inhibitor/GSK-3 or inhibitor/JAK complex and determining the amount of radiolabel bound. Alternatively, inhibitor binding may be determined by running a competition experiment where new inhibitors are 25 incubated with GSK-3 or JAK bound to known radioligands. Detailed conditions for assaying a compound utilized in this invention as an inhibitor of GSK-3 or JAK kinase are set forth in the Examples below.

[0049] According to another embodiment, the invention provides a composition comprising a compound of this invention or a pharmaceutically acceptable derivative

thereof and a pharmaceutically acceptable carrier, adjuvant, or vehicle. The amount of compound in the compositions of this invention is such that is effective to detectably inhibit a protein kinase, particularly GSK-
5 3 or JAK kinase, in a biological sample or in a patient. Preferably the composition of this invention is formulated for administration to a patient in need of such composition. Most preferably, the composition of this invention is formulated for oral administration to a
10 patient.

[0050] The term "patient", as used herein, means an animal, preferably a mammal, and most preferably a human.
[0051] The term "pharmaceutically acceptable carrier, adjuvant, or vehicle" refers to a non-toxic carrier,
15 adjuvant, or vehicle that does not destroy the pharmacological activity of the compound with which it is formulated. Pharmaceutically acceptable carriers, adjuvants or vehicles that may be used in the compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or
20 electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium
25 carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.

[0052] The term "detectably inhibit", as used herein means a measurable change in GSK-3 or JAK activity between a sample comprising said composition and a GSK-3 or JAK kinase and an equivalent sample comprising GSK-3 or JAK kinase in the absence of said composition.

5 [0053] As used herein, the term "JAK" is used interchangeably with the terms "JAK kinase" and "a JAK family kinase". Preferably JAK refers to JAK3 kinase.

10 [0054] A "pharmaceutically acceptable derivative" means any non-toxic salt, ester, salt of an ester or other derivative of a compound of this invention that, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention or an inhibitorily active metabolite or residue thereof. As used herein, the term "inhibitorily active metabolite or residue thereof" means that a metabolite or residue thereof is also an inhibitor of a GSK-3 or JAK family kinase.

15 [0055] Pharmaceutically acceptable salts of the compounds of this invention include those derived from pharmaceutically acceptable inorganic and organic acids and bases. Examples of suitable acid salts include acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptanoate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, salicylate,

succinate, sulfate, tartrate, thiocyanate, tosylate and undecanoate. Other acids, such as oxalic, while not in themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in 5 obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts.

[0056] Salts derived from appropriate bases include alkali metal (e.g., sodium and potassium), alkaline earth metal (e.g., magnesium), ammonium and $N^+(C_{1-4}\text{ alkyl})_4$, 10 salts. This invention also envisions the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Water or oil-soluble or dispersible products may be obtained by such quaternization.

[0057] The compositions of the present invention may 15 be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, 20 intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. Preferably, the compositions are administered orally, intraperitoneally or intravenously. Sterile injectable forms of the compositions of this invention may be 25 aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension 30 in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium

chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium.

[0058] For this purpose, any bland fixed oil may be

5 employed including synthetic mono- or di-glycerides.

Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their

10 polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents that are commonly used in the formulation of pharmaceutically acceptable dosage forms

15 including emulsions and suspensions. Other commonly used surfactants, such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for

20 the purposes of formulation.

[0059] The pharmaceutically acceptable compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions. In

25 the case of tablets for oral use, carriers commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added.

For oral administration in a capsule form, useful diluents include lactose and dried cornstarch. When

30 aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.

[0060] Alternatively, the pharmaceutically acceptable compositions of this invention may be administered in the form of suppositories for rectal administration. These can be prepared by mixing the agent with a suitable non-
5 irritating excipient that is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug. Such materials include cocoa butter, beeswax and polyethylene glycols.

[0061] The pharmaceutically acceptable compositions of
10 this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are
15 readily prepared for each of these areas or organs.

[0062] Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal patches may also be used.

20 [0063] For topical applications, the pharmaceutically acceptable compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers. Carriers for topical administration of the compounds of this invention
25 include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. Alternatively, the pharmaceutically acceptable compositions can be formulated in a suitable
30 lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate,

- 40 -

polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.

[0064] For ophthalmic use, the pharmaceutically acceptable compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride. Alternatively, for ophthalmic uses, the pharmaceutically acceptable compositions may be formulated in an ointment such as petrolatum.

[0065] The pharmaceutically acceptable compositions of this invention may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.

[0066] Most preferably, the pharmaceutically acceptable compositions of this invention are formulated for oral administration.

[0067] The amount of the compounds of the present invention that may be combined with the carrier materials to produce a composition in a single dosage form will vary depending upon the host treated, the particular mode of administration. Preferably, the compositions should be formulated so that a dosage of between 0.01 - 100 mg/kg body weight/day of the inhibitor can be administered to a patient receiving these compositions.

[0068] It should also be understood that a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the

- 41 -

activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity 5 of the particular disease being treated. The amount of a compound of the present invention in the composition will also depend upon the particular compound in the composition.

[0069] Depending upon the particular condition, or 10 disease, to be treated or prevented, additional therapeutic agents, which are normally administered to treat or prevent that condition, may also be present in the compositions of this invention. As used herein, additional therapeutic agents that are normally 15 administered to treat or prevent a particular disease, or condition, are known as "appropriate for the disease, or condition, being treated".

[0070] For example, chemotherapeutic agents or other anti-proliferative agents may be combined with the 20 compounds of this invention to treat proliferative diseases and cancer. Examples of known chemotherapeutic agents include, but are not limited to, Gleevec™, adriamycin, dexamethasone, vincristine, cyclophosphamide, fluorouracil, topotecan, taxol, interferons, and platinum 25 derivatives.

[0071] Other examples of agents the inhibitors of this invention may also be combined with include, without limitation: treatments for Alzheimer's Disease such as Aricept® and Excelon®; treatments for Parkinson's Disease 30 such as L-DOPA/carbidopa, entacapone, ropinrole, pramipexole, bromocriptine, pergolide, trihexyphenidyl, and amantadine; agents for treating Multiple Sclerosis (MS) such as beta interferon (e.g., Avonex® and Rebif®),

Copaxone[®], and mitoxantrone; treatments for asthma such as albuterol and Singulair[®]; agents for treating schizophrenia such as zyprexa, risperdal, seroquel, and haloperidol; anti-inflammatory agents such as

5 corticosteroids, TNF blockers, IL-1 RA, azathioprine, cyclophosphamide, and sulfasalazine; immunomodulatory and immunosuppressive agents such as cyclosporin, tacrolimus, rapamycin, mycophenolate mofetil, interferons, corticosteroids, cyclophosphamide, azathioprine, and

10 sulfasalazine; neurotrophic factors such as acetylcholinesterase inhibitors, MAO inhibitors, interferons, anti-convulsants, ion channel blockers, riluzole, and anti-Parkinsonian agents; agents for treating cardiovascular disease such as beta-blockers,

15 ACE inhibitors, diuretics, nitrates, calcium channel blockers, and statins; agents for treating liver disease such as corticosteroids, cholestyramine, interferons, and anti-viral agents; agents for treating blood disorders such as corticosteroids, anti-leukemic agents, and growth

20 factors; and agents for treating immunodeficiency disorders such as gamma globulin.

[0072] The amount of additional therapeutic agent present in the compositions of this invention will be no more than the amount that would normally be administered in a composition comprising that therapeutic agent as the only active agent. Preferably the amount of additional therapeutic agent in the presently disclosed compositions will range from about 50% to about 100% of the amount normally present in a composition comprising that agent as the only therapeutically active agent.

[0073] According to another embodiment, the invention relates to a method of inhibiting GSK-3 or JAK kinase activity in a biological sample comprising the step of

contacting said biological sample with a compound of this invention, or a composition comprising said compound.

[0074] The term "biological sample", as used herein, includes, without limitation, cell cultures or extracts thereof; biopsied material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof.

[0075] Inhibition of GSK-3 or JAK kinase activity in a biological sample is useful for a variety of purposes that are known to one of skill in the art. Examples of such purposes include, but are not limited to, blood transfusion, organ-transplantation, biological specimen storage, and biological assays.

[0076] According to another embodiment, the invention provides a method for treating or lessening the severity of a GSK-3-mediated disease or condition in a patient comprising the step of administering to said patient a composition according to the present invention.

[0077] The term "GSK-3-mediated condition", as used herein means any disease or other deleterious condition in which GSK-3, is known to play a role. Such diseases or conditions include, without limitation, diabetes, Alzheimer's disease, Huntington's, Parkinson's, AIDS associated dementia, amyotrophic lateral sclerosis (AML), multiple sclerosis (MS), schizophrenia, cardiomyocyte hypertrophy, ischemia/reperfusion and baldness.

[0078] According to another embodiment, the invention provides a method for treating or lessening the severity of a JAK-mediated disease or condition in a patient comprising the step of administering to said patient a composition according to the present invention.

[0079] The term "JAK-mediated disease", as used herein means any disease or other deleterious condition in which

a JAK family kinase, in particular JAK3, is known to play a role. Such conditions include, without limitation, immune responses such as allergic or type I hypersensitivity reactions, asthma, autoimmune diseases such as transplant rejection, graft versus host disease, rheumatoid arthritis, amyotrophic lateral sclerosis, and multiple sclerosis, neurodegenerative disorders such as Familial amyotrophic lateral sclerosis (FALS), as well as in solid and hematologic malignancies such as leukemias and lymphomas.

[0080] In an alternate embodiment, the methods of this invention that utilize compositions that do not contain an additional therapeutic agent, comprise the additional step of separately administering to said patient an additional therapeutic agent. When these additional therapeutic agents are administered separately they may be administered to the patient prior to, sequentially with or following administration of the compositions of this invention.

[0081] The compounds of this invention or pharmaceutically acceptable compositions thereof may also be incorporated into compositions for coating an implantable medical device, such as prostheses, artificial valves, vascular grafts, stents and catheters.

Vascular stents, for example, have been used to overcome restenosis (re-narrowing of the vessel wall after injury). However, patients using stents or other implantable devices risk clot formation or platelet activation. These unwanted effects may be prevented or mitigated by pre-coating the device with a pharmaceutically acceptable composition comprising a kinase inhibitor. Suitable coatings and the general preparation of coated implantable devices are described

- 45 -

- in US Patents 6,099,562; 5,886,026; and 5,304,121. The coatings are typically biocompatible polymeric materials such as a hydrogel polymer, polymethyldisiloxane, polycaprolactone, polyethylene glycol, polylactic acid, 5 ethylene vinyl acetate, and mixtures thereof. The coatings may optionally be further covered by a suitable topcoat of fluorosilicone, polysaccharides, polyethylene glycol, phospholipids or combinations thereof to impart controlled release characteristics in the composition.
- 10 Implantable devices coated with a compound of this invention are another embodiment of the present invention.

[0082] In order that the invention described herein may be more fully understood, the following examples are 15 set forth. It should be understood that these examples are for illustrative purposes only and are not to be construed as limiting this invention in any manner.

Synthetic Examples

20 Example 1. N-phenylguanidine

[0083] Aniline (30 mmol, 1 equiv.), cyanamide (1.3 g, 31 mmol, 1.03 equiv.), and 4N hydrogen chloride in dioxane (8 mL, 32 mmol) was stirred for 10 minutes at room temperature and heated to 80°C for 18 hours. The 25 mixture was diluted with water (30 mL) and diethyl ether (50 mL). The aqueous layer was washed with ether (30 mL) and the organic layers were discarded. The aqueous layer was neutralized with 6N aqueous HCl (6 mL) and diluted with ethyl acetate (50 mL). The aqueous layer was 30 extracted with ethyl acetate (50 mL) four times. The combined organic layers were concentrated under reduced pressure to afford a solid compound. The solid was

- 46 -


washed with diethyl ether (30 mL) to provide pale yellow title compound. The compound was characterized by LC/MS and HPLC.

[0084] The following arylguanidine intermediates were 5 prepared by the procedure described above in Example 1 except the aniline was replaced with the appropriate arylamine: *N*-(4-fluoro-phenyl)-guanidine; *N*-(6-chloro-pyridin-3-yl)-guanidine; *N*-(3-chloro-phenyl)-guanidine; *N*-(3-methoxy-phenyl)-guanidine; *N*-(3-benzyloxy-phenyl)-guanidine; 4-guanidino-benzenesulfonamide; 3-guanidino-benzenesulfonamide.

[0085] The following synthetic intermediates were obtained commercially (from Bionet): 1-[3-phenyl-benzo[c]isoxazol-5-yl]-ethanone; 1-[3-(4-fluoro-phenyl)-benzo[c]isoxazol-5-yl]-ethanone; 1-[3-(4-chloro-phenyl)-benzo[c]isoxazol-5-yl]-ethanone; 3-dimethylamino-1-(3-phenyl-benzo[c]isoxazol-5-yl)-propenone; 3-dimethylamino-1-[3-(4-fluoro-phenyl)-benzo[c]isoxazol-5-yl]-propenone; 3-dimethylamino-1-[3-(4-chloro-phenyl)-benzo[c]isoxazol-5-yl]-propenone; and 1-(4-nitro-phenyl)-3-dimethylamino-propenone.

Example 2. Phenyl-[4-(3-phenyl-benzo[c]isoxazol-5-yl)-pyrimidin-2-yl]-amine (Compound I-A1)

25




[0086] 3-Dimethylamino-1-(5-methyl-3-methylsulfanyl-1-phenyl-1*H*-pyrazol-4-yl)-propenone (30 mg, 0.1 mmol) and 30 N-phenylguanidine (15 mg, 1.1 equiv.) were slurried in acetonitrile (0.5 mL) and heated at 100°C for 24 hours.

- 47 -

The mixture was diluted with methanol (2 mL) and heated briefly and cooled. The resulting solid was filtered and washed with methanol (1 mL). The solid was dried under reduced pressure to afford the title compound. The
5 compound was characterized by LC/MS and HPLC.

Example 3. (4-Fluoro-phenyl)-[4-(3-phenyl-benzo[c]isoxazol-5-yl)-pyrimidin-2-yl]-amine (Compound I-A2)

10




15

[0087] Compound I-A2 was prepared according to the procedure described above in Example 2 except that N-phenylguanidine was replaced by N-(4-fluoro-phenyl)-guanidine.

Example 4. (6-Chloro-pyridin-3-yl)-[4-(3-phenyl-benzo[c]isoxazol-5-yl)-pyrimidin-2-yl]-amine (Compound I-A3)

20




25

[0088] Compound I-A3 was prepared according to the procedure described above in Example 2 except that N-phenylguanidine was replaced by N-(6-chloro-pyridin-3-yl)-guanidine.

30


Example 5. (3-Chloro-phenyl)-[4-(3-phenyl-benzo[c]isoxazol-5-yl)-pyrimidin-2-yl]-amine (Compound I-A4)



[0089] Compound I-A4 was prepared according to the procedure described above in Example 2 except that N-phenylguanidine was replaced by N-(3-chloro-phenyl)-guanidine.

Example 6. 4-[4-(3-Phenyl-benzo[c]isoxazol-5-yl)-pyrimidin-2-ylamino]-benzenesulfonamide (Compound I-A19)


10



[0090] Compound I-A19 was prepared according to the procedure described above in Example 2 except that N-phenylguanidine was replaced by 4-guanidino-benzenesulfonamide.

Example 7. N-{4-[3-(4-Chlorophenyl)-benzo[c]isoxazol-5-yl]-pyrimidin-2-yl}-acetamide (I-A22).

20



Step A. 4-[3-(4-Chlorophenyl)-benzo[c]isoxazol-5-yl]-pyrimidin-2-ylamine.

[0091] To a mixture of sodium pellets (14 mg, 0.609 mmol) in methanol (1 mL) at room temperature, was added guanidine hydrochloride (10 mg, 0.105 mmol) and commercially available 1-[3-(4-chlorophenyl)-benzo[c]isoxazole-5-yl]-3-

- 49 -

dimethylamino-propenone (50 mg, 0.153 mmol). The reaction mixture was heated at 80 °C for 18 hours. The mixture was cooled to room temperature and diluted with water (6 mL). The granular precipitate was filtered, dissolved in 5 dichloromethane, then dried over magnesium sulfate. Purification by silica gel chromatography (4:1 ethyl acetate/hexane) gave 4-[3-(4-chlorophenyl)-benzo[c]isoxazol-5-yl]-pyrimidin-2-ylamine as a yellow solid (35 mg, 98% yield). ^1H NMR (500 MHz, d_6 -DMSO) δ 8.68 (s, 1H), 8.35 (d, 1H), 8.25-8.19 (m, 3H), 7.82-7.80 (m, 1H), 7.78-7.72 (m, 2H), 10 7.4 (d, 1H), 6.79 (s, 1H) ppm. LC-MS (ES+) m/e= 323.04 (M+H).


Step B. N-{4-[3-(4-Chorophenyl)-benzo[c]isoxazol-5-yl]-15 pyrimidin-2-yl}-acetamide.

[0092] To a suspension of 4-[3-(4-chlorophenyl)-benzo[c]isoxazol-5-yl]-pyrimidin-2-ylamine in toluene (1.5 mL) at room temperature, was added acetic anhydride (0.5 mL). The mixture was heated at 100 °C for 3 hours. The reaction 20 mixture was diluted with water (6 mL) and the precipitate filtered, then washed with toluene (2 x 6 mL). Purification was achieved by silica gel chromatography (4:1 ethyl acetate/hexane then 2% methanol/dichloromethane), followed by a 5% aqueous sodium bicarbonate wash (1 x 50 mL) to give the title compound as a yellow solid (12 mg, 30% yield). ^1H NMR (500 MHz, d_6 -DMSO) δ 10.62 (s, 1H), 8.85 (s, 1H), 8.75 (d, 1H), 8.31 (d, 1H), 8.25 (d, 2H), 8.02 (d, 1H), 7.85 (d, 1H), 25 7.75 (d, 2H), 2.3 (s, 3H) ppm. LC-MS (ES+) m/e= 365.13 (M+H).

30


Example 8. {4-[3-(4-Chlorophenyl)-benzo[c]isoxazol-5-yl]-pyrimidin-2-yl}-methylamine (I-A23).

- 50 -



[0093] This compound was prepared in an analogous manner to that described in Example 2 using 1-methylguanidine hydrochloride to yield the title compound as a yellow solid (30 mg, 98% yield). ^1H NMR (500 MHz, d_6 -DMSO) δ 8.7 (s, 1H), 8.41 (s, 1H), 8.31-8.2 (m, 3H), 7.82 (d, 1H), 7.72 (d, 2H), 7.38 (d, 1H), 7.25-7.2 (m, 1H), 2.95-2.85 (m, 3H) ppm. LC-MS (ES+) m/e= 337.04 (M+H).


10 Example 9. 3-(4-Chlorophenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)-benzo[c]isoxazole (I-A24).



[0094] This compound was prepared according to the procedure described in Example 13, Step E, except using morpholinoformamidine hydrobromide to yield 3-(4-chlorophenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)-benzo[c]isoxazole as a yellow solid (30 mg, 98% yield). ^1H NMR (500 MHz, d_6 -DMSO) δ 8.7 (s, 1H), 8.5 (d, 1H), 8.3-8.22 (m, 3H), 7.82 (s, 1H), 7.75 (d, 2H), 7.55 (d, 1H), 3.85-3.8 (m, 4H), 3.75-3.68 (m, 4H) ppm. LC-MS (ES+) m/e= 393.13 (M+H).

25 Example 10. 4-[3-(4-Piperidin-1-yl-phenyl)-benzo[c]isoxazol-5-yl]pyrimidin-2-ylamine (I-A32)

- 51 -



Step A. 5-(2-Methyl-[1,3]dioxolan-2-yl)-3-(4-piperidin-1-yl-phenyl)benzo[c]isoxazole

- 5 **[0095]** This compound was prepared in a manner analogous to that described in Example 13, Step B except starting with piperidine and a reaction duration of 2.5 h, giving the title compound, after purification, as a bright yellow solid (174 mg, 69% yield). ^1H NMR (500 MHz, CDCl_3) δ 8.02-7.81 (m, 3H), 7.53 (d, $J=9.25$ Hz, 1H), 7.10-6.92 (m, 2H), 4.15-3.96 (m, 2H), 3.94-3.71 (m, 2H), 3.47-3.23 (m, 4H), 1.83-1.60 (m, 9H). LC-MS (ES+) m/e = 365.19 ($\text{M}+\text{H}$).
- 10 **Step B. 1-[3-(4-Piperidin-1-yl-phenyl)-benzo[c]isoxazol-5-yl]ethanone**
- 15 **[0096]** This compound was prepared in a manner analogous to that described in Experiment 17, Step C giving the title compound as an orange oil (42.6 mg, 97% yield). ^1H NMR (500 MHz, CDCl_3) δ 8.57-8.47 (m, 1H), 8.01-7.91 (m, 2H), 7.88 (dd, $J=1.5$, 9.4 Hz, 1H), 7.55 (dd, 0.85, 9.4 Hz, 1H), 7.08-6.94 (m, 2H), 3.46-3.30 (m, 4H), 2.66 (s, 3H), 1.82-1.59 (m, 6H). LC-MS (ES+) m/e = 321.1 ($\text{M}+\text{H}$).
- 20 **Step C. 4-[3-(4-Piperidin-1-yl-phenyl)-benzo[c]isoxazol-5-yl]pyrimidin-2-ylamine (I-A32)**
- 25 **[0097]** This compound was prepared in a manner analogous to that described in Experiment 17, Steps D & E giving the title compound as an orange solid (30 mg, 70%

- 52 -

yield from 1-[3-(4-piperidin-1-yl-phenyl)-
benzo[c]isoxazol-5-yl]ethanone). ^1H NMR (500 MHz, CDCl_3)
 δ 8.58 (s, 1H), 8.38 (d, $J=5.25$ Hz, 1H), 8.06-7.85 (m,
3H), 7.62 (d, $J=9.4$ Hz, 1H), 7.16-6.92 (m, 3H), 5.19-4.91
5 (br s, 2H), 3.45-3.25 (m, 4H), 1.82-1.61 (m, 6H). HPLC
(cyano column) 14.26 min. LC-MS (ES+) m/e= 372.2 (M+H).

Example 11. 4-[3-(3-Piperidin-1-yl-phenyl)-benzo[c]
isoxazol-5-yl]-pyrimidin-2-ylamine (I-A33)

10



Step A. 3-(3-Bromophenyl)-5-(2-methyl-[1,3]dioxolan-2-
yl)benzo[c]isoxazole

15 [0098] To a solution of KOH (58g, 1.03mol) in MeOH
(200 mL) at room temperature was added a solution of 2-
methyl-2-(4-nitro-phenyl)-[1,3]dioxolane (10.7g, 0.051
mol) and 3-bromophenylacetonitrile (11.34g, 0.058 mol) in
MeOH (100 mL). The mixture was stirred at room
20 temperature under a stream of nitrogen for 4 days. The
product was isolated according to the procedure given in
Example 15 Step A (8.5g, 46% yield). ^1H NMR (500 MHz,
 CDCl_3) δ 8.19-8.15 (m, 1H), 7.97 (d, 4.0 Hz, 1H), 7.90 (s,
1H), 7.67-7.59 (m, 2H), 7.50-7.40 (m, 2H), 4.15-4.03 (m,
2H), 1.71 (s, 3H). LC-MS ES+ m/e= 361.96 (M+H).

Step B. 3-Dimethylamino-1-[3-(3-piperidin-1-yl-phenyl)-
benzo[c]isoxazol-5-yl]-propanone

[0099] This was prepared according to the procedure
30 described in Example 13 to give the title compound as a


- 53 -

brown solid (141 mg, 48% yield from 3-(3-bromophenyl)-5-(2-methyl-[1,3]dioxolan-2-yl)benzo[c]isoxazole). ^1H NMR (500 MHz, DMSO-d₆) δ 8.50 (s, 1H), 8.09-7.89 (m, 1H), 7.89-7.64 (m, 2H), 7.63-7.45 (m, 3H), 7.42-7.13 (m, 1H), 6.01 (d, J=12.2 Hz, 1H), 3.51-3.27 (m, 4H), 3.26-3.07 (m, 3H), 3.06-2.80 (m, 3H), 1.84-1.42 (m, 6H). LC-MS ES+). m/e= 371.31 (M+H). HPLC (cyano column) 14.13 minutes.

Step C. 4-[3-(3-Piperidin-1-yl-phenyl)-benzo[c]isoxazol-5-yl]-pyrimidin-2-ylamine (I-A33)

[0100] This compound was prepared in a manner analogous to that described in Experiment 17, Step E. The title compound was isolated as a yellow/brown solid (97 mg, 69%). ^1H NMR (500 MHz, CDCl₃) δ 8.56 (s, 1H), 8.39 (d, J=5.2 Hz, 1H), 7.97 (dd, J=1.3, 9.4 Hz, 1H), 7.69 (d, 9.5 Hz, 1H), 7.63-7.53 (m, 1H), 7.52-7.37 (m, 2H), 7.17-7.02 (m, 2H), 5.16 (br s, 2H), 3.39-3.19 (m, 4H), 1.86-1.53 (m, 6H). LC-MS ES+). m/e= 361.96 (M+H). HPLC (cyano column) 12.01 minutes.

Example 12. 4-[4-(4-Nitro-phenyl)-pyrimidin-2-ylamino]-benzenesulfonamide




25

[0101] 1-(4-Nitro-phenyl)-3-dimethylamino-propenone (3 mmol) and 4-guanidino-benzenesulfonamide (3.3 mmol) in acetonitrile (1 mL) was refluxed for 36 hours. The mixture was diluted with methanol (5 mL) and cooled to room temperature. The yellow solid was filtered and washed with methanol (3 mL) and dried under reduced

- 54 -

pressure to afford title compound. The compound was characterized by LC/MS and HPLC.

5 Example 13. 4-[3-(4-Morpholin-4-yl-phenyl)benzo[c]isoxazol-5-yl]pyrimidin-2-yl amine (I-A34)



Step A. 3-(4-Bromo-phenyl)-5-(2-methyl-[1,3]-dioxolan-2-yl)-benzo[c]isoxazole

[0102] To solution of KOH (28.46 g, 508 mmol) in MeOH (50 mL) at 0-10°C was added a solution of 4-bromophenylacetonitrile (6.32g, 32.2 mmol) and 2-methyl-2-(4-nitro-phenyl)-[1,3]-dioxolane (I) (5.35g, 25.6 mmol) in MeOH (15 mL). The mixture was stirred at room temperature under nitrogen for 18 hours giving a thick slurry. Water (100 mL) was added and the precipitate was filtered, and was washed with water (2 x 75 mL). The solid was dissolved in hot CH₂Cl₂, filtered and evaporated to give a brown solid. Repeated triturations with Et₂O gave the product as a bright orange solid (5.19 g, 56% yield). ¹H NMR (500 MHz, CDCl₃) δ 7.99-7.68 (m, 1H), 7.79-7.68 (m, 2H), 7.66-7.54 (m, 1H), 7.52-7.40 (m, 1H), 4.17-4.04 (m, 2H), 3.92-3.78 (m, 2H), 1.70 (s, 3H) ppm.

LC-MS (ES+) m/e= 361.9 (M+H).

Step B. 5-(2-Methyl-[1,3]-dioxolan-2-yl)-3-(4-morpholin-4-yl-phenyl)-benzo[c]isoxazole

[0103] A flame dried, argon flushed flask was charged with 3-(4-bromo-phenyl)-5-(2-methyl-[1,3]-dioxolan-2-yl)-benzo[c]isoxazole (199.6 mg, 0.56 mmol), Pd(OAc)₂ (5 mg,

- 55 -

0.02 mmol), P(tBu)₃ (30 μ L of 10% solution in toluene, 0.012 mmol), NaOtBu (78.8 mg, 0.82 mmol) and morpholine (150 μ L, 1.72 mmol) in anhydrous toluene (1 mL). The mixture was heated at 80°C under Argon for 3 hours. The solvent was evaporated, and purification by flash chromatography (SiO₂) eluting initially with 1:9 EtOAc:hexanes to 3:7 EtOAc:hexanes provided the title compound as bright yellow solid (49 mg, 24% yield). ¹H NMR (500 MHz, CDCl₃) δ 7.96 (d, 2H), 7.91 (s, 1H), 7.55 (d, J=9.35 Hz, 1H), 7.47-7.34 (m, 1H), 7.04 (d, J=8.95 Hz, 2H), 4.17-4.01 (m, 2H), 3.95-3.76 (m, 6H), 3.31 (t, J=5 Hz, 4H), 1.7 (s, 3H). HPLC (cyano column) 8.61 minutes

15 Step C. 1-[3-(4-Morpholin-4-yl-phenyl)benzo[c]isoxazol-5-yl]ethanone

[0104] A solution of 5-(2-methyl-[1,3]-dioxolan-2-yl)-3-(4-morpholin-4-yl-phenyl)-benzo[c]isoxazole (37 mg, 0.10 mmol) in formic acid (88% solution, 1.5 mL) was stirred at room temperature for 70 minutes. The formic acid was removed *in vacuo*, and the resultant solid was dissolved in CH₂Cl₂, dried over sodium sulfate, filtered and evaporated to give the product as an orange solid (1.42g, 87% yield). ¹H NMR (500 MHz, DMSO-d6) δ 8.51 (s, 1H), 7.99 (d, J=8.9 Hz, 2H), 7.88 (d, J=1.0 Hz, 1H), 7.58 (d, 9.4 Hz, 1H), 3.90 (t, J=4.8 Hz, 4H), 3.35 (t, J=5.0 Hz, 4H), 2.66 (s, 3H). LC-MS (ES+) m/e= 323.09 (M+H).

Step D. 3-Dimethylamino-1-[3-(4-morpholino-4-yl-phenyl)-benzo[c]isoxazol-5-yl]propanone

[0105] A solution of 1-[3-(4-morpholin-4-yl-phenyl)-benzo[c]isoxazol-5-yl]ethanone (25 mg, 0.08 mmol) in DMF


- 56 -

(2.5 mL) was treated with DMF-DMA (50 μ L, 0.37 mmol) and was heated at 90°C for 36 hours and for 100°C for a further 18hours. The solvent was evaporated to give the crude product as brown oil (35.2 mg) which was used directly in the next step without purification. LC-MS (ES+) m/e= 378.2 (M+H).
5

Step E. 4-[3-(4-Morpholin-4-yl-phenyl)benzo[c]isoxazol-5-yl]pyrimidin-2-yl amine (I-A34)

10 [0106] To a solution of sodium (spheres, 25 mg, 1.08 mmol) in MeOH (0.7 mL) at room temperature under nitrogen was added guanidine hydrochloride (10 mg, 0.105 mmol) and a solution of 3-dimethylamino-1-[3-(4-morpholino-4-yl-phenyl)-benzo[c]isoxazol-5-yl]propenone (0.08 mmol) in MeOH (1.5 mL) and the reaction was heated to 90°C for 18 hours. The resulting precipitate was filtered to give the product as an orange solid (25 mg, 84% yield). 1 H NMR (500 MHz, DMSO-d6) δ 8.61 (s, 1H), 8.33 (d, 1H), 7.98-8.10 (m, 3H), 7.23-6.98 (m, 3H), 3.96-3.75 (m, 4H), 3.43-3.30 (m, 4H), 2.62-2.49 (m, 2H). LC-MS (ES+) m/e= 374.18 (M+H), HPLC (cyano column) 9.42 minutes.
15
20

25 Example 14. 4-{4-[3-(3,4-Dimethoxy-phenyl)-benzo[c]isoxazol-5-yl]-pyrimidin-2-ylamino}-benzenesulfonamide (Compound I-A35)




[0107] A mixture of 4-[(4-Nitro-phenyl)-pyrimidin-2-ylamino]-benzenesulfonamide (0.2 mmol) and 3,4-

30

- 57 -

dimethoxy-phenylacetonitrile (0.4 mmol) in dimethyl sulfoxide (2 mL) was treated with 20% sodium ethoxide in ethanol (0.5 mL) at ice bath temperature. The mixture was stirred at room temperature for 18 hours and diluted 5 with methanol (2 mL). Solid was collected and redissolved in methanol (3 mL) and heated 10 minutes at 80 °C and cooled to room temperature. The solid was recrystallized twice in methanol to afford yellow title compound. The compound was characterized by LC/MS and 10 HPLC.

Example 15. 4-[3-(4-Bromophenyl)-benzo[c]isoxazol-5-yl]-pyrimidin-2-ylamine (I-A36).



15 Step A. 1-[3-(4-Bromophenyl)-benzo[c]isoxazol-5-yl]-ethanone
[0108] A solution of 3-(4-bromo-phenyl)-5-(2-methyl-[1,3]-dioxolan-2-yl)-benzo[c]isoxazole (Example 1, Step A) (2.13 g, 5.93 mmol) in formic acid (88% solution, 50 ml) was stirred at room temperature for 30 minutes, 20 affording a thick yellow precipitate. The formic acid was removed *in vacuo*, and the resultant solid was dissolved in CH₂Cl₂, dried over sodium sulfate, filtered and evaporated to give the product as an orange solid (1.42 g, 76% yield). ¹H NMR (500 MHz, CDCl₃) δ 8.47 (s, 1H), 8.04-7.85 (m, 3H), 7.85-7.71 (m, 2H), 7.72-7.57 (m, 1H), 2.68 (s, 3H). HPLC (cyano column) 17.68 minutes

Step B. 1-[3-(4-Bromo-phenyl)-benzo[c]isoxazol-5-yl]-3-30 dimethylamino-propenone

[0109] This compound was prepared from [3-(4-bromophenyl)-benzo[c]isoxazol-5-yl]-ethanone in an analogous manner to Experiment 15, Step D except that the reaction duration was 18 hours. The product was isolated
5 as a brown solid and was used in the next step without purification (1.61 g, 97% yield). ^1H NMR (500 MHz, CDCl_3)
d 8.84 (s, 1H), 7.98-7.79 (m, 4H), 7.77-7.67 (m, 2H),
7.66-7.51 (m, 1H), 5.67 (d, $J=12.2$ Hz, 1H), 3.31-2.78 (m,
6H).


10

Step C. 4-[3-(4-Bromophenyl)-benzo[c]isoxazol-5-yl]-pyrimidin-2-ylamine

[0110] This compound was prepared in an analogous manner to 4-[3-(4-chlorophenyl)-benzo[c]isoxazol-5-yl]-pyrimidin-2-ylamine (see Example 13). Purification was achieved by
15 trituration with dichloromethane to yield 4-[3-(4-bromophenyl)-benzo[c]isoxazol-5-yl]-pyrimidin-2-ylamine as a yellow solid (559 mg, 49% yield). ^1H NMR (500 MHz, d_6 -DMSO) δ 8.67 (s, 1H), 8.36 (d, 1H), 8.2-8.13 (m, 3H), 7.88
20 (d, 2H), 7.82 (d, 1H), 7.39 (d, 1H), 6.78 (s, 1H) ppm. LC-MS (ES+) m/e= 367 ($M+\text{H}$).

Example 16. 3-[4-(3-Phenyl-benzo[c]isoxazol-5-yl)-pyrimidin-2-ylamino]-benzenesulfonamide (Compound I-A37)

25



[0111] Compound I-A37 was prepared according to the procedure described above in Example 2 except that N-phenylguanidine was replaced by 3-guanidino-benzenesulfonamide.
30

Example 17. N-(4-{3-[3-(2,5-Dimethoxy-pyrimidin-4-yl)-phenyl]-benzo[c]isoxazol-5-yl}-pyrimidin-2-yl)-acetamide (Compound I-A50).

5



Step A: N-(4-[3-(3-Bromophenyl)-benzo[c]isoxazol-5-yl]-pyrimidin-2-yl)-acetamide

[0112] Compound I-A50 was prepared according to the procedure described as above in Example 7 step B utilizing 4-[3-(3-bromophenyl)-benzo[c]isoxazol-5-yl]-pyrimidin-2-ylamine instead of 4-[3-(4-Chlorophenyl)-benzo[c]isoxazol-5-yl]-pyrimidin-2-ylamine. Material was isolated, by removal of the solvent under reduced pressure and trituration with dichloromethane, as a yellow powder (430 mg, 77% yield). ^1H NMR (500 MHz TFA-d) δ 9.15 (s, 1H), 8.85 (d, 1H), 8.41 (d, 1H), 8.38 (s, 1H), 8.32 (d, 1H), 8.17 (d, 1H), 8.05 (d, 1H), 7.94 (d, 1H), 7.64 (dd, 1H), 2.67 (s, 3H) in ppm. LC-MS (ES+) m/e=409 (M+H).


Step B: N-(4-{3-[3-(2,5-Dimethoxy-pyrimidin-4-yl)-phenyl]-benzo[c]isoxazol-5-yl}-pyrimidin-2-yl)-acetamide

[0113] A flask was charged with N-(4-[3-(3-bromophenyl)-benzo[c]isoxazol-5-yl]-pyrimidin-2-yl)-acetamide (100 mg, 0.272 mmol), cesium carbonate (97.7 mg, 0.328 mmol), and 2,5-dimethoxypyrimidine-6-boronic acid (55.0 mg, 0.3 mmol). The flask was evacuated and back-filled with nitrogen 5-7 times before adding 5 mL of degassed p-dioxane and 1 mL of degassed DMF. To this

- 60 -

stirring solution/suspension was added, 125 μ L of a 10% w/v benzene solution of tri-tertbutylphosphine followed by the addition of $Pd_2(dba)_3$ (25 mg, 0.0272 mmol) slurred in 1 mL of degassed DMF. The reaction was stirred under 5 nitrogen atmosphere, at 80°C. Reaction was followed by HPLC and deemed to be complete in 4 hours. The reaction mixture was suction filtered hot through a pad of diatomaceous earth and washed the precipitate with DMF and acetonitrile. The filtrate was reduced to an oil under reduced pressure and the crude material purified via HPLC utilizing acetonitrile/water/TFA as the eluent. 10 The material was isolated as a bright yellow powder (15 mg, 13% yield). 1H NMR (500 MHz DMSO-d6) δ 8.93 (s, 1H), 8.6 (s, 1H), 8.31 (s, 1H), 8.29 (d, 1H), 8.25 (d, 1H), 15 8.07 (d, 1H), 7.87 (d, 1H), 7.81 (d, 1H), 7.77 (m, 1H), 4.02 (2 close sing, 6H) in ppm. LC-MS (ES+) m/e=469 (M+H)

Example 18. {4-[3-(3-Bromo-phenyl)-benzo[c]isoxazol-5-yl]-
20 pyrimidin-2-yl}-carbamic acid ethyl ester (Compound I-A55).




[0114] To a stirring solution of 4-[3-(3-bromophenyl)-
25 benzo[c]isoxazol-5-yl]-pyrimidin-2-ylamine (75 mg; 0.205 mmol) in 1 mL of p-dioxane and 0.5 mL of DMSO, was added 40 μ L (45.6 mg, 0.42 mmol) of ethyl chloroformate followed by 73 μ L (54.3 mg, 0.42 mmol) of diisopropylethylamine. The reaction was stirred at 50°C, 30 in a sealed vessel, for 8 hours. The solvents were

- 61 -

removed under vacuo and the crude material was purified via HPLC with acetonitrile/water/TFA as the eluent. The material was isolated as a yellow powder (30 mg, 32% yield). ^1H NMR (500 MHz, DMSO-d₆) δ 10.5 (br s, 1H), 8.9 (s, 1H), 8.75 (d, 1H), 8.35 (m, 3H), 8.3 (s, 1H), 8.0 (d, 1H), 7.89 (t, 2H), 7.65 (t, 1H), 4.2 (q, 2H), 1.26 (t, 3H) in ppm. LC-MS (ES+) m/e=439/441 (M+H)

10 Example 19. Thiophene-2-carboxylic acid {4-[3-(3-bromo-phenyl)-benzo[c]isoxazol-5-yl]-pyrimidin-2-yl}-amide
(Compound I-A 56)



[0115] 4-[3-(3-bromophenyl)-benzo[c]isoxazol-5-yl]-
15 pyrimidin-2-ylamine (100 mg; 0.272 mmol) was dissolved in
3 mL of a mixture (2:1) of dry DMF/THF and stirred under
a nitrogen atmosphere at ambient temperature. Sodium
hydride (15 mg, 0.375 mmol, 60% oil dispersion) was added
To the reaction and stirred for 30 minutes.
20 Thiophenecarbonylchloride (32 μL ; 43.7 mg; 0.299 mmol) in
500 μL of dry DMF was added dropwise over 2 minutes and
the reaction was stirred for 18 hours at ambient
temperature. Workup was affected by removing the
solvents under reduced pressure and the resulting residue
25 was triturated with methyltertbutyl ether. The crude
solid was purified via silica column chromatography with
5% ethanol in methylenechloride to yield 32 mg of a tan
powder; 24% yield. ^1H NMR (500 MHz, DMSO-d₆) δ 11.2 (s,
1H), 8.92 (s, 1H), 8.88 (d, 1H), 8.39 (d, 1H), 8.35 (s,
30 1H), 8.3 (d, 1H), 8.23 (d, 1H), 8.15 (d, 1H), 7.95 (d,

- 62 -

1H), 7.9 (d, 1H), 7.87 (d, 1H), 7.65 (t, 1H), 7.24 (t, 1H) in ppm. LC-MS (ES+) m/e=477/479 (M+H).

Biological Methods

5 IC₅₀ Determination for the Inhibition of GSK-3

[0116] Compounds were screened for their ability to inhibit GSK-3 β (Amino Acids 1-420) activity using a standard coupled enzyme system (Fox et al. (1998) *Protein Sci.* 7, 2249). Reactions were carried out in a solution containing 100 mM HEPES (pH 7.5), 10 mM MgCl₂, 25 mM NaCl, 300 μ M NADH, 1 mM DTT and 1.5% DMSO. Final substrate concentrations in the assay were 10 μ M ATP (Sigma Chemicals, St Louis, MO) and 300 μ M peptide (HSSPHQS(PO₃H₂)EDEEE, American Peptide, Sunnyvale, CA).

10 Reactions were carried out at 30°C and 60 nM GSK-3 β . Final concentrations of the components of the coupled enzyme system were 2.5 mM phosphoenolpyruvate, 300 μ M NADH, 30 μ g/ml pyruvate kinase and 10 μ g/ml lactate dehydrogenase.

15 [0117] An assay stock buffer solution was prepared containing all of the reagents listed above with the exception of ATP and the test compound of interest. 59 μ l of the test reaction was placed in a 96 well 1/2 diameter plate (Corning, Corning, NY) then treated with 1 20 μ l of a 2 mM DMSO stock containing the test compound (final compound concentration 30 μ M). The plate was incubated for about 10 minutes at 30°C then the reaction initiated by addition of 7 μ l of ATP (final concentration 10 μ M). Rates of reaction were obtained using a 30 Molecular Devices Spectramax plate reader (Sunnyvale, CA) over a 5 minute read time at 30°C. Compounds showing greater than 50% inhibition versus standard wells

containing DMSO, but no compound, were titrated and IC₅₀ values were determined using a similar protocol in standard 96 well plates with the assay scaled to a final volume of 200 μ l.

5 [0118] In the GSK-3 inhibition assay described above, many of the compounds of this invention that were tested were found to provide an IC₅₀ value below one micromolar.

K_i Determination for the Inhibition of GSK-3

10 [0119] Compounds were screened for their ability to inhibit GSK-3 β (Amino Acids 1-420) activity using a standard coupled enzyme system (Fox et al. (1998) *Protein Sci.* 7, 2249). Reactions were carried out in a solution containing 100 mM HEPES (pH 7.5), 10 mM MgCl₂, 25 mM NaCl,

15 300 μ M NADH, 1 mM DTT and 1.5% DMSO. Final substrate concentrations in the assay were 20 μ M ATP (Sigma Chemicals, St Louis, MO) and 300 μ M peptide (HSSPHQS(PO₃H₂)EDEEE, American Peptide, Sunnyvale, CA).

Reactions were carried out at 30°C and 20 nM GSK-3 β .

20 Final concentrations of the components of the coupled enzyme system were 2.5 mM phosphoenolpyruvate, 300 μ M NADH, 30 μ g/ml pyruvate kinase and 10 μ g/ml lactate dehydrogenase.

[0120] An assay stock buffer solution was prepared
25 containing all of the reagents listed above with the exception of ATP and the test compound of interest. The assay stock buffer solution (175 μ l) was incubated in a 96 well plate with 5 μ l of the test compound of interest at final concentrations spanning 0.002 μ M to 30 μ M at 30°C
30 for 10 minutes. Typically, a 12 point titration was conducted by preparing serial dilutions (from 10 mM compound stocks) with DMSO of the test compounds in

daughter plates. The reaction was initiated by the addition of 20 μ l of ATP (final concentration 20 μ M). Rates of reaction were obtained using a Molecular Devices Spectramax plate reader (Sunnyvale, CA) over 10 min at 30 °C. The K_i values were determined from the rate data as a function of inhibitor concentration.

[0121] In the GSK-3 inhibition assay described above, many of the compounds of this invention that were tested were found to provide a K_i value below one micromolar.

10

JAK Inhibition Assay

[0122] Compound inhibition of JAK were assayed by the method described by G. R. Brown, et al, *Bioorg. Med. Chem. Lett.* 2000, vol. 10, pp 575-579 in the following manner. Into Maxisorb plates, previously coated at 4°C with Poly (Glu, Ala, Tyr) 6:3:1 then washed with phosphate buffered saline 0.05% and Tween (PBST), was added 2 μ M ATP, 5 mM MgCl₂, and a solution of compound in DMSO. The reaction was started with JAK enzyme and the plates incubated for 60 minutes at 30°C. The plates were then washed with PBST, 100 μ L HRP-Conjugated 4G10 antibody was added, and the plate incubated for 90 minutes at 30°C. The plate was again washed with PBST, 100 μ L TMB solution is added, and the plates were incubated for another 30 minutes at 30°C. Sulfuric acid (100 μ L of 1M) was added to stop the reaction and the plate is read at 450 nm to obtain the optical densities for analysis to determine IC₅₀ values.


[0123] While we have described a number of embodiments of this invention, it is apparent that our basic examples

- 65 -

may be altered to provide other embodiments which utilize the compounds and methods of this invention. Therefore, it will be appreciated that the scope of this invention is to be defined by the appended claims rather than by 5 the specific embodiments which have been represented by way of example.

Claims:

1. A compound of formula I:



I

or a pharmaceutically acceptable derivative or prodrug thereof, wherein:

A-B is N-O or O-N;

Ar is an optionally substituted C₅₋₁₀ aryl group;

T is a C₁₋₄ alkylidene chain wherein one or two methylene units of T are optionally and independently replaced by O, NR, S, C(O), C(O)NR, NRC(O)NR, SO₂, SO₂NR, NRSO₂, NRSO₂NR, CO₂, OC(O), NRCO₂, or OC(O)NR;

n is zero or one;

R¹ is hydrogen or an optionally substituted group selected from C₁₋₁₀ aliphatic, C₅₋₁₀ aryl, C₆₋₁₂ aralkyl, C₃₋₁₀ heterocyclyl, or C₄₋₁₂ heterocyclylalkyl;

each R² is independently selected from R, halo, CN, OR, N(R)₂, SR, C(=O)R, CO₂R, CONR₂, NRC(=O)R, NRCO₂(C₁₋₆ aliphatic), OC(=O)R, SO₂R, S(=O)R, SO₂NR₂, or NRSO₂(C₁₋₆ aliphatic);

each R³ is independently selected from R, halo, CN, OR, N(R)₂, SR, C(=O)R, CO₂R, CONR₂, NRC(=O)R, NRCO₂(C₁₋₆ aliphatic), OC(=O)R, SO₂R, S(=O)R, SO₂NR₂, or NRSO₂(C₁₋₆ aliphatic); and

each R is independently selected from hydrogen, a C₁₋₈ aliphatic group, or two R on the same nitrogen are taken together with the nitrogen to form a 4-8 membered

heterocyclic ring having 1-3 heteroatoms selected from nitrogen, oxygen or sulfur.

2. The compound of claim 1 wherein the compound is a 2,1-benzisoxazole.

3. The compounds of claim 2 wherein each R² is independently hydrogen or a C₁₋₄ alkyl group and each R³ is independently selected from hydrogen, halo -O(C₁₋₄ alkyl), or C₁₋₄ alkyl.

4. The compound of claim 3 wherein Ar is a substituted or unsubstituted five or six-membered aromatic ring having zero to two heteroatoms selected from nitrogen, sulfur, and oxygen.

5. The compound of claim 4 wherein Ar is a substituted or unsubstituted six-membered aromatic ring having zero to two ring nitrogen atoms.

6. The compound of claim 5 wherein Ar is a phenyl ring optionally substituted by one or more substituents independently selected from C₁₋₁₀ aliphatic, C₅₋₁₀ aryl, C₆₋₁₂ aralkyl, C₃₋₁₀ heterocyclyl, C₄₋₁₂ heterocyclylalkyl, halo, CN, OR, N(R)₂, SR, C(=O)R, CO₂R, CONR₂, NRC(=O)R, NRCO₂(C₁₋₆ aliphatic), OC(=O)R, SO₂R, S(=O)R, SO₂NR₂, or NRSO₂(C₁₋₆ aliphatic), or two substituents on adjacent positions are optionally taken together with their intervening atoms to form a fused 5-8 membered unsaturated or partially unsaturated ring having zero to two heteroatoms selected from nitrogen, oxygen or sulfur.






7. The compound of claim 6 wherein R¹ is a phenyl or pyridyl ring optionally substituted with






- 68 -

halogen, -R, -OR, -OH, -SH, -SR, protected OH, -NO₂, -CN, -NH₂, -NHR, -N(R)₂, -NHCOR, -NHCONHR, -NHCON(R)₂, -NRCOR, -NHCO₂R, -CO₂R, -CO₂H, -COR, -CONHR, -CON(R)₂, -S(O)₂R, -SO₂NH₂, -S(O)R, -SO₂NHR, or -NHS(O)₂R, wherein R is an aliphatic group or a substituted aliphatic group having one to three carbons.







8. The compound of claim 7 wherein R¹ is substituted by -SO₂NH₂ or -SO₂NHR.

9. The compound of claim 1 wherein the compound is selected from any one of the following:







No.	Structure
I-A1	
I-A2	
I-A3	
I-A4	
I-A5	

No.	Structure
I-A6	
I-A7	
I-A8	
I-A9	
I-A10	
I-A11	
I-A12	








- 70 -







No.	Structure
I-A13	
I-A14	
I-A15	
I-A16	
I-A17	
I-A18	
I-A19	

- 71 -






No.	Structure
I-A20	
I-A21	
I-A22	
I-A23	
I-A24	
I-A25	

No.	Structure
I-A26	
I-A27	
I-A28	
I-A29	
I-A30	
I-A31	
I-A32	







No.	Structure
I-A33	
I-A34	
I-A35	
I-A36	
I-A37	
I-A38	
I-A39	







No.	Structure
I-A40	
I-A41	
I-A42	
I-A43	
I-A44	
I-A45	







No.	Structure
I-A46	
I-A47	
I-A48	
I-A49	
I-A50	
I-A51	

No.	Structure
I-A52	
I-A53	
I-A54	
I-A55	
I-A56	
I-A57	






No.	Structure
I-A58	
I-A59	
I-A60	
I-A61	
I-A62	
I-A63	




No.	Structure
I-A64	
I-A65	
I-A66	
I-A67	
I-A68	
I-A69	

No.	Structure
I-A70	
I-A71	
I-A72	
I-A73	
I-A74	
I-A75	

No.	Structure
I-A76	
I-A77	
I-A78	
I-A79	
I-A80	
I-A81	

- 81 -

No.	Structure
I-A82	
I-A83	
I-A84	
I-A85	
I-A86	

No.	Structure
I-A87	
I-A88	
I-A89	

10. A composition comprising a compound according to claim 1 in an amount to detectably inhibit GSK-3 or JAK protein kinase activity, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

11. The composition according to claim 10, additionally comprising an additional therapeutic agent selected from an a chemotherapeutic or anti-proliferative agent, a treatment for Alzheimer's Disease, a treatment for Parkinson's Disease, an agent for treating Multiple Sclerosis (MS), a treatment for asthma, an anti-inflammatory agent, an immunomodulatory or immunosuppressive agent, a neurotrophic factor, an agent for treating cardiovascular disease, an agent for

treating liver disease, an agent for treating a blood disorder, or an agent for treating an immunodeficiency disorder.

12. A method of inhibiting GSK-3 or JAK kinase activity in a biological sample, comprising the step of contacting said biological sample with:

- a) a composition according to claim 10; or
- b) a compound according to claim 1.

13. A method of treating or lessening the severity of a GSK-3- or JAK-mediated disease or condition in a patient, comprising the step of administering to said patient:

- a) a composition according to claim 10; or
- b) a compound according to claim 1.

14. The method according to claim 13, wherein said GSK-3-mediated disease is selected from diabetes, Alzheimer's disease, Huntington's disease, Parkinson's, AIDS-associated dementia, amyotrophic lateral sclerosis (AML), multiple sclerosis (MS), schizophrenia, cardiomyocyte hypertrophy, ischemia/reperfusion and baldness.

15. The method according to claim 13, wherein said JAK-mediated disease is selected from an immune response, an autoimmune disease, a neurodegenerative disease, or a solid or hematologic malignancy.

16. The method according to claim 15, wherein said JAK-mediated disease is selected from an allergic or type I hypersensitivity reaction, asthma, transplant rejection, graft versus host disease, rheumatoid arthritis, amyotrophic lateral sclerosis, multiple

- 85 -

20. A composition for coating an implantable device comprising a compound according to claim 1 and a carrier suitable for coating said implantable device.

21. An implantable device coated with a composition according to claim 20.

INTERNATIONAL SEARCH REPORT

b International Application No
PCT/US 02/19186

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D413/04 C07D401/14 C07D409/14 A61K31/505 A61P3/10
A61P25/28 A61P37/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 97 19065 A (CELLTECH THERAPEUTICS LTD.) 29 May 1997 (1997-05-29) page 6, line 5; claims 1-10	1-21
Y	WO 01 12621 A (VERTEX PHARMACEUTICALS INC.) 22 February 2001 (2001-02-22) claims 1-24	1-21
Y	US 6 093 716 A (P. D. DAVIS ET AL.) 25 July 2000 (2000-07-25) claims 1-7	1-21
Y	WO 01 29009 A (CELLTECH CHIROSCIENCE LTD.) 26 April 2001 (2001-04-26) claims 1- ---	1-21
	-/-	

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority, claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

24 September 2002

Date of mailing of the international search report

10/10/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Herz, C

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/US 02/19186

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, Y	WO 01 72745 A (CYCLACELL LTD.) 4 October 2001 (2001-10-04) claims 1-25 ---	1-21
Y	WO 01 00214 A (MERCK & CO., INC.) 4 January 2001 (2001-01-04) claims 1-44 ---	1-21
Y	WO 01 00207 A (MERCK & CO., INC.) 4 January 2001 (2001-01-04) claims 1-44 ---	1-21
Y	J. ZIMMERMANN ET AL.: "Potent and selective inhibitors of the ABL-kinase: Phenylaminopyrimidine (PAP) derivatives" BIOORG. MED. CHEM. LETT., vol. 7, no. 2, 1997, pages 187-192, XP002214446 tables 1,2 ---	1-21
Y	WO 00 78731 A (CELLTECH CHIROSCIENCE LTD.) 28 December 2000 (2000-12-28) page 4, line 8; claims 1-11 -----	1-21

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No	
PCT/US 02/19186	

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
WO 9719065	A 29-05-1997	AU EP WO US US	7631496 A 0862560 A1 9719065 A1 6235746 B1 5958935 A	11-06-1997 09-09-1998 29-05-1997 22-05-2001 28-09-1999
WO 0112621	A 22-02-2001	AU CZ EP NO WO	6909600 A 20020534 A3 1218369 A1 20020713 A 0112621 A1	13-03-2001 17-07-2002 03-07-2002 12-04-2002 22-02-2001
US 6093716	A 25-07-2000	AU EP WO JP	4308397 A 0929549 A1 9811095 A1 2001500153 T	02-04-1998 21-07-1999 19-03-1998 09-01-2001
WO 0129009	A 26-04-2001	AU EP WO	7935100 A 1222175 A1 0129009 A1	30-04-2001 17-07-2002 26-04-2001
WO 0172745	A 04-10-2001	AU WO GB US	4262901 A 0172745 A1 2361236 A ,B 2002019404 A1	08-10-2001 04-10-2001 17-10-2001 14-02-2002
WO 0100214	A 04-01-2001	AU EP WO US	5889100 A 1194152 A1 0100214 A1 6316444 B1	31-01-2001 10-04-2002 04-01-2001 13-11-2001
WO 0100207	A 04-01-2001	AU EP WO US	6605200 A 1206260 A1 0100207 A1 6329380 B1	31-01-2001 22-05-2002 04-01-2001 11-12-2001
WO 0078731	A 28-12-2000	AU BG BR CZ DE EP WO GB NO	5548800 A 106116 A 0011770 A 20014583 A3 10084704 T0 1187816 A1 0078731 A1 2369360 A 20015162 A	09-01-2001 31-07-2002 05-03-2002 15-05-2002 29-05-2002 20-03-2002 28-12-2000 29-05-2002 18-02-2002